Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GJB2 | P29033 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15304344 | 1.00 | MAPK1 (0.34) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL9971203 | 1.00 | MAPK1 (0.34) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL25597683 | 0.86 | GJB2 (0.38) | MAPK1LGALS8LGALS3LGALS4GJB2 | |
| SCHEMBL15935858 | 0.85 | LGALS8 (0.41) | MAPK1LGALS8LGALS3L3MBTL1CA1 | |
| SCHEMBL13073700 | 0.81 | LGALS8 (0.44) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL10820762 | 0.81 | SLC2A1 (0.37) | LGALS8LGALS3LGALS4GAA | |
| SCHEMBL26262226 | 0.81 | LGALS3 (0.40) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL9968286 | 0.81 | LGALS8 (0.31) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL14511583 | 0.81 | L3MBTL1 (0.36) | LGALS8LGALS3LGALS4L3MBTL1MAPT | |
| SCHEMBL13241371 | 0.81 | LGALS8 (0.31) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | POLN, NT5C3B, PCNA | MAPK1 3279/4885LGALS8 2402/4885LGALS3 3294/4885 |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | POLN, POLRMT, POLM | MAPK1 4161/4885LGALS8 1120/4885LGALS3 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.